NEW YORK (360Dx) – Chembio Diagnostics on Monday said that it has established an "at-the-market" program to offer up to $21.2 million of its common stock from time to time.

The firm said net proceeds from the ATM program will be used to fund possible acquisitions, invest in business operations, and as working capital. Cantor Fitzgerald is the sales agent for the program. Sales of Chembio's common stock under the ATM may be made through the Nasdaq Capital Market, among other methods.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.